Buparlisib (BKM120)

For research use only. Not for use in humans.

目录号：S2247 别名： NVP-BKM120 中文名称：布帕尼西

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2227.95	现货
5mg	RMB 1400.12	现货
10mg	RMB 2607.65	现货
50mg	RMB 7928.28	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Buparlisib (BKM120)发表文献222篇：

Cancer Cell, 2022, S1535-6108(22)00005-8

PubMed: 35120601 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00284-1

PubMed: 34171264 ( click the link to review the publication )

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Immunol, 2020, 21(4):442-454

PubMed: 32152508 ( click the link to review the publication )

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Cell, 2012, 27;149(3):656-70.

PubMed: 22541435 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Elife, 2022, 11e73796

PubMed: 35156921 ( click the link to review the publication )

Cancers (Basel), 2022, 14(6)1575

PubMed: 35326726 ( click the link to review the publication )

Adv Sci (Weinh), 2021, e2103360

PubMed: 34918496 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00232-X

PubMed: 33909988 ( click the link to review the publication )
Nat Commun, 2021, 12(1):5053

PubMed: 34417459 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1920

PubMed: 33772001 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3140

PubMed: 34035258 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-3359

PubMed: 34921025 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-1943

PubMed: 34921019 ( click the link to review the publication )

Theranostics, 2021, 11(8):3552-3564

PubMed: 33664847 ( click the link to review the publication )

Cancer Res, 2021, 81(21):5540-5554

PubMed: 34518212 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):546

PubMed: 34039959 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):400

PubMed: 33854046 ( click the link to review the publication )

Cancer Discov, 2021, candisc.1265.2020

PubMed: 34911733 ( click the link to review the publication )

Front Oncol, 2021, 11:782065

PubMed: 34820336 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):24

PubMed: 33407478 ( click the link to review the publication )

Bioorg Chem, 2021, 117:105405

PubMed: 34649154 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01074-2

PubMed: 32963347 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )
Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16208

PubMed: 33004905 ( click the link to review the publication )

Front Neurosci, 2020, 2;14:223

PubMed: 32300287 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Genes Cancer, 2020, 11(3-4):106-121

PubMed: 33488949 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Small GTPases, 2020, 10.1080/21541248

PubMed: 32043900 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )

Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )
Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E37

PubMed: 30609754 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2774-2788

PubMed: 31911861 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )

Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Front Oncol, 2019, 9:1119

PubMed: 31750239 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Biochem J, 2019, 476(23):3583-3593

PubMed: 31738383 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )
Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )

Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Elife, 2018, 7e33718

PubMed: 30475204 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )

Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29535262 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1526-1539

PubMed: 29654068 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2049-2059

PubMed: 29970482 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )
Sci Rep, 2018, 8(1):10784

PubMed: 30018387 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )

Breast Cancer Res, 2017, 19(1):105

PubMed: 28886748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )
Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52474-52487

PubMed: 28881745 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1324-1335

PubMed: 27870828 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

PLoS Biol, 2016, 14(11):e1002581

PubMed: 27880766 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45414-45428

PubMed: 27323778 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )
Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Glia, 2015, 63(10):1850-9

PubMed: 25944104 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1194-209

PubMed: 26293922 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Cell Signal, 2015, 27(12):2389-400

PubMed: 26363466 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10399-414

PubMed: 25871383 ( click the link to review the publication )
Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5459-72

PubMed: 23796563 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )
Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Cell Commun Signal, 2013, 11(1):3

PubMed: 23311350 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

BKM120是可用于口服的生物有效的PI3K抑制剂。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	点击更多
52 nM	116 nM	166 nM	262 nM	2.4 μM	点击更多

体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。^[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。^[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。^[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
glioma cell lines	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mm[3O\|Jp		NEDHWYRKSzVyPUGtNu69VQ>?	NWHWZmtJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwOlUxQDBpPkKyNFY2ODhyPD;hQi=>
U87	MWPBdI9xfG:\|aYOgRZN{[Xl?	NEXjbnEz\|ryP	M2i3O\|czcA>?		MkDHbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO=	M4i1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
SNU-601	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWfIZlFbPzKq	MWDEUXNQ	M1rTRWlEPTB;MD64NVbDuTBwME[z{txO	NVnReJBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-1	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUi3Nog>	MUTEUXNQ	NITYe\|lKSzVyPUGuNFgzyrFyLkCyPO69VQ>?	M2G0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-668	M4[0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmHsO\|Jp	NX25NoJOTE2VTx?=	MlmzTWM2OD1zLkW3PeKyOC5yN{VOwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
AGS	M1i4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUO3Nog>	NXHsWYtiTE2VTx?=	NWXzN3FmUUN3ME2xMlcyPMLzMD6xNVfPxE1?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-216	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGrzeFk4Omh?	Mly2SG1UVw>?	NHXKcJpKSzVyPUKuOlkzyrFyLkC4Nu69VQ>?	NXr5[ZVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-5	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHWySWQ4Omh?	NVLPSZJYTE2VTx?=	NX3BSIhTUUN3ME2xMlM2OcLzMD6wPVHPxE1?	NGfNb2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-638	NXTyZ3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEDofpE4Omh?	NEXXWpJFVVOR	NXK5OnJ3UUN3ME2yMlI5OsLzMD6wOVPPxE1?	NH\CXZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-16	M1r0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnnJO\|Jp	NVG4b\|hQTE2VTx?=	MXvJR\|UxRTFwNUezxtExNjByMd88US=>	NFPqVJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-484	NIPUXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MofYO\|Jp	NIS1ZVJFVVOR	NWXqd3VjUUN3ME2xMlczQMLzMD6wOFXPxE1?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-620	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGq0XII4Omh?	M1y4[WROW09?	Mkf4TWM2OD1{LkmzPeKyOC5yMEJOwG0>	NFfOTXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-719	NWLpZXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF\Y[Fc4Omh?	NYHUS4xSTE2VTx?=	NGnFOHdKSzVyPUOuNFM4yrFyLkCzNu69VQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
MM cell lines	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\1TFEx\|ryP	NWS4W4xqOjSq	NYXnTIp[TE2VTx?=	MoXoTWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm	M1H6WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC3OFg2Lz5{MkKwO\|Q5PTxxYU6=
ARP-1	NWO4cJNCSXCxcITvd4l{KEG\|c3H5	M3XNd\|Ex\|ryP	MUiyOIg>	MVrEUXNQ	NVnnSFVOcW6mdXPld{BOVSClZXzsJIFxd3C2b4Ppd{B1cHKxdXfoJINie3Cjc3WgZYN1cX[jdHnvci=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyN{S4OUc,OjJ{MEe0PFU9N2F-
colon cancer cell lines	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrYc2kxNTFyzszN	MW[3Nog>	Ml3OSG1UVw>?	NFS4dm1KSzVyPUJOwG0>	NEG3Oog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
gastric cancer cell lines	NV[5NGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYi2fZB[OC1zMN88US=>	Mki1O\|Jp	MlW1SG1UVw>?	M4TBVWlEPTB;Mj21{txO	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
HCT-116/HT-29/MKN-45	Mn:zRZBweHSxc3nzJGF{e2G7	MlfhNu69VQ>?	M2XOUVQ5cA>?		M2PSZZNpcW[2IHnuJGczKHCqYYPl	M2H5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
HT-29 and HCT-116	MV7DZZNx[XOnIHHzd4F6	MYi1{txO	MXOyOIg>		MXjpcoR2[2W\|IHPhd5Bie2ViYXP0bZZqfHl?	NFXv[Zk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
PIK3CA-mutant MCF7	NWDGdGo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDXRmlIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?=	MX:3Nog>		NEGzO3RIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2O{c,OjJ4NUO5Olc9N2F-
PIK3CA-mutant MCF7	NHS3UIlMcW6jc3WgRZN{[Xl?	MVzJR\|UxRTFzNNMxN45O	MVO3Nog>		MUjJR\|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:\|cHjvdplt[XSrb36gcIV3\Wy\|	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2O{c,OjJ4NUO5Olc9N2F-
MCF7-myr-Akt	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfFTG9XT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2=	NHi4VmM4Omh?		NYC5WnkzT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ3M{m2O{c,OjJ4NUO5Olc9N2F-
Y1 cell line	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrNdXAxNjIQvF2vNe69VQ>?	M4DycFI1cA>?	M{T3VGROW09?	MlX4bY5pcWKrdIOgOlDwxIViY3XscEB3cWGkaXzpeJkhcW5iTYnjMXNkfHJvdILhcpNn\WO2ZXSgZ4VtdHN?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ7MkmwOEc,OjJ4OUK5NFQ9N2F-
human NSCLC	NInnTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf4NE42NTMQvF2=	Mnf0O\|Jp		MVzJR\|UxRTIQvF2=	NXzhN\|hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3PFE{QTNpPkKyO\|gyOzl\|PD;hQi=>
human NSCLC	NYDmTZJ3U2mwYYPlJGF{e2G7	M4fa[lHPxE1?	MojQNlRp		M{m0OIlvcGmkaYTzJJRp\SCDa4SvcXRQWiC\|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS=	M1HUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ixN\|k{Lz5{Mke4NVM6OzxxYU6=
JVM2	MlTqR5l1d3SxeHnjbZR6KGG\|c3H5	NGWxc3UxNjJvMkFOwG0>	M{\sVlczcA>?	NXjJSmhpTE2VTx?=	MVHJR\|UxRTBwOd88US=>	MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N\|koRjJ\|MkO4OlM6RC:jPh?=
EHEB	NFntdYVEgXSxdH;4bYNqfHliYYPzZZk>	MUSwMlIuOjEQvF2=	Ml;1O\|Jp	MWXEUXNQ	NX;2WFloUUN3ME2wMlfPxE1?	MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N\|koRjJ\|MkO4OlM6RC:jPh?=
MEC2	MkDkR5l1d3SxeHnjbZR6KGG\|c3H5	NV7QfGR7OC5{LUKw{txO	MVy3Nog>	MojxSG1UVw>?	NXfiPFN1UUN3ME2wMlfPxE1?	M4PpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
primary B-CLL lymphocytes	MkL3RZBweHSxc3nzJGF{e2G7	M3TWT2lEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV?	M3PUd\|I1cA>?	MlzUSG1UVw>?	NVm5SIRqUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>?	NV35PJNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|g3OzlpPkKzNlM5PjN7PD;hQi=>
primary B-CLL lymphocytes	NGi5dmlMcW6jc3WgRZN{[Xl?	MUjJR\|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m	MUWyOIg>		M1e5[4lvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO\|aX;u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|OE[zPUc,OjN{M{i2N\|k9N2F-
SK-HEP1	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DqdlEuOjEQvF2=	MYe3Nog>	MXfEUXNQ	NHfDcnNKSzVy78{cNe69VQ>?	NWTRWJFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|kyOzZpPkKzOFc6OTN4PD;hQi=>
786-0	M3T1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[wNU0zOM7:TR?=	NFXTXGE4Omh?	MVzEUXNQ	NGPxWYZKSzVy78{cNe69VQ>?	NEPxdmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3PVE{Pid-MkO0O\|kyOzZ:L3G+
human HCC cell lines	M2O0OGNmdGxidnnhZoltcXS7IHHzd4F6	NUn0SZRYOC5yMEWtNe69VQ>?	NF7rXHI1QGh?		M1vLfGlEPTB;Md88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OUm5PUc,OjN2OEm5PVk9N2F-
Huh7	Ml70T4lv[XOnIFHzd4F6	NYjteG1JOc7:TR?=	M1HwbVQ5cA>?		MXTzbYdvce,ugXPhcpRtgSC{ZXT1Z4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S=	Mn7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEm5PVkoRjJ\|NEi5PVk6RC:jPh?=
human NSCLC cell lines	MnvkRZBweHSxc3nzJGF{e2G7	M2\nfFAvOTJ3LUVOwG0>	NFvSV\|gzPGh?	M4PocGROW09?	MWfJR\|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?=	M4XzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[yOFczLz5{M{W2NlQ4OjxxYU6=
Primary CLL cells	MYnBdI9xfG:\|aYOgRZN{[Xl?	MlXyNU0yOM7:TR?=	MnyzOFhp		MYLpcoR2[2W\|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEiwO{c,OjN6NUC4NFc9N2F-
Primary CLL cells	M1LodGtqdmG\|ZTDBd5NigQ>?	M3fzblLPxE1?	M3jsR\|MxdWmw		MVHk[YNz\WG\|ZXSgVGk{UyCjY4Tpeol1gQ>?	M4TseVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEWwPFA4Lz5{M{i1NFgxPzxxYU6=
Primary CLL cells	NG\pWZpEgXSxdH;4bYMhSXO\|YYm=	NVHkVoU6Os7:TR?=	NHTKZXQzPGh?		NV3ZT45PcW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=>	NIq5SpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1NFgxPyd-MkO4OVA5ODd:L3G+
LC-1/SQSF	NVPZWIxHTnWwY4Tpc44hSXO\|YYm=	NFnkO3k{\|ryP	MXiyOIg>	NGHjVm5FVVOR	NWr3T4o5\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt	NGfUNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m4NFA6Oyd-MkO5PFAxQTN:L3G+
BCR-ABL	M17zdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PFbVAvOjVvMUFOwG0>	NGDyUZA1\A>?		Mkf2d4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NE[xNkc,OjR{NES2NVI9N2F-
T-ALL	Mnm3RZBweHSxc3nzJGF{e2G7	NFzHdWhj\XS5ZXXuJFEvPCCjbnSgOU4{KG2PIHH0JFI1cCCjbnSgNE46KGGwZDC1MlUhdU1iYYSgOFhpKGmwIHTp[oZmemWwdDDj[YxtKGyrbnW=	M3fRWlI1KG:{IES4bC=>	NX\1c\|hjTE2VTx?=	M3nuSYFn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz	MkH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MUC3N\|YoRjJ2M{GwO\|M3RC:jPh?=
H1975	NV3CVW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rzWlAvOy17LkdOwG0>	NVewWnpQPzKq	M37FZmROW09?	M3HvS2lEPTB;MT6zPFXPxE1?	NX;nTlJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|c5PDZpPkK0N\|M4QDR4PD;hQi=>
H1975	NGOwO\|BCeG:ydH;zbZMhSXO\|YYm=	NYO1TZM3Os7:TR?=	MUOyOIg>	MmH6SG1UVw>?	MkPTbY5kemWjc3XzJIFxd3C2b4Ppd{Bz[XSnIIPp[45q\mmlYX70cJk>	NFjWS4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzO\|g1Pid-MkSzN\|c5PDZ:L3G+
BON	NWDveVVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzRNU02\|ryP	NFfLXmc4Omh?		NInmVHJl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v	NFL3UW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0N\|UzOyd-MkS0OFM2OjN:L3G+
BON	MV\BdI9xfG:\|aYOgRZN{[Xl?	NVrtW4gxOS13zszN	M1[xSVI1cA>?		M{n0PYlv[3KnYYPld{BieG:ydH;zbZM>	M1;lUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NESzOVI{Lz5{NES0N\|UzOzxxYU6=
GBM	MULBdI9xfG:\|aYOgRZN{[Xl?	MoPhNu69VQ>?	NWfLXpFjPDiq	NVXnOZN1TE2VTx?=	MkH0bY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyMES5Nkc,OjR3MEC0PVI9N2F-
FaDu	NVTkb4dUTnWwY4Tpc44hSXO\|YYm=	M3jlSlUh\|ryP	MVGyOEBp	NUPKSXg{TE2VTx?=	M1GySXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUG0O{c,OjR4M{GxOFc9N2F-
EMT6	MWfGeY5kfGmxbjDBd5NigQ>?	MWW1JO69VQ>?	MYGyOEBp	M4\qcGROW09?	MWDS[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	NXPIN3dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|EyPDdpPkK0OlMyOTR5PD;hQi=>
HCT116	MW\GeY5kfGmxbjDBd5NigQ>?	NHi4fFU2KM7:TR?=	MmT6NlQhcA>?	NX21bop7TE2VTx?=	NIjZfnpT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=>	MnL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
U87	MXvGeY5kfGmxbjDBd5NigQ>?	MY[1JO69VQ>?	MkjFNlQhcA>?	MmTCSG1UVw>?	M{H6bXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	NF;hZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N\|EyPDd:L3G+
Saos-2	NGTWbmZHfW6ldHnvckBCe3OjeR?=	NELaN3g2OCEQvF2=	MYC0PEBp		Mlu0TY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>?	NFf6OYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63	NF3NSZdHfW6ldHnvckBCe3OjeR?=	NXjvVow1PTBizszN	Mo[3OFghcA>?		MYPJcohq[mm2czDj[YxtKGmwdnHzbY9v	NUHXR4NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
SJSA-1	M1jWb2Z2dmO2aX;uJGF{e2G7	MXK1NEDPxE1?	M4TUelQ5KGh?		M1jCRWlvcGmkaYTzJINmdGxiaX72ZZNqd25?	NFm4VlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
Saos-2	NUf3WGRGTnWwY4Tpc44hSXO\|YYm=	MnniOVAh\|ryP	M2rJXlQ5KGh?		Mkf6TY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW\|c3nvci=>	NHfLR2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63	MX3GeY5kfGmxbjDBd5NigQ>?	MWK1NEDPxE1?	M2SzNFQ5KGh?		NYjtTXNbUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	MoLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
SJSA-1	MVPGeY5kfGmxbjDBd5NigQ>?	NUjCeY94PTBizszN	M3zGN\|Q5KGh?		MY\Jcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO\|aX;u	M4PlR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
Saos-2	NV;hcIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorLOVAh\|ryP	NVXQXHQ6PDhiaB?=		MUnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	M1HpflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
MG-63	NFLpZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;FNGF[PTBizszN	Mkm0OFghcA>?		MnqyTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	NICzW5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1	M2HXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;aOVAh\|ryP	NUW5RpVWPDhiaB?=		M{G0N2lvcGmkaYTzJINmdGxidnnhZoltcXS7	NYDVbHR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
LN18	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzENlAh\|ryP	NYDzdVZ5PzJiaB?=	MlnnSG1UVw>?	M2jzd2lEPTB:NTFOwG0>	M{W0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
LN229	NH:xd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYGyNEDPxE1?	MmDXO\|IhcA>?	NFXMfodFVVOR	M1jVWWlEPTB:NTFOwG0>	NYrSUm9xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
LNZ308	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TvbFIxKM7:TR?=	NUDoTXhPPzJiaB?=	M3LxZ2ROW09?	NHnRVpBKSzVyPEWg{txO	NIOzV5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
T98G	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv4WHNwOjBizszN	NXrQWFhMPzJiaB?=	NUPSR\|V6TE2VTx?=	NXPZVJM{UUN3MEy1JO69VQ>?	NIf0b2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
U87	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3OxUlIxKM7:TR?=	M4rJ[lczKGh?	NXTTTVhMTE2VTx?=	NXvYSFJvUUN3MEy1JO69VQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
LN18	M3PJbWZ2dmO2aX;uJGF{e2G7	M1fse\|Uh\|ryP	MUeyOEBp	MX3EUXNQ	NE[wcINKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuW	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
LNZ308	M37qbGZ2dmO2aX;uJGF{e2G7	NHzqepI2KM7:TR?=	MV6yOEBp	MlrKSG1UVw>?	NFTzTIZKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuW	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
MDA-MB-175	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XrWlEh\|ryP	NHy4XY42KGR?	M3LTZ2ROW09?	MnTjTWM2ODxzIN88US=>	Ml;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-134	NWPqeZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIr2PWgyKM7:TR?=	NIjDfYc2KGR?	M{jPSWROW09?	NUXYWpI5UUN3MEyxJO69VQ>?	MmXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1500	NXfxbWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYKxJO69VQ>?	M1\QTVUh\A>?	Mle2SG1UVw>?	MoDyTWM2ODxzIN88US=>	M37wZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
EFM-19	NVTLOFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3e2OVEh\|ryP	NF7YN2k2KGR?	MUPEUXNQ	M1n1OWlEPTB:MTFOwG0>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
ZR-75-30	M3\YS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWxJO69VQ>?	M4nlSlUh\A>?	MVTEUXNQ	NIDRWXNKSzVyPEGg{txO	M3;kdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-361	M3\xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf0NG1LOSEQvF2=	NFTj[Gw2KGR?	NFPTSWRFVVOR	M1fK[mlEPTB:MTFOwG0>	M173b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
T-47D	NU\JSItbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS1OWNiOSEQvF2=	MUm1JIQ>	M3PB[GROW09?	Mk\QTWM2ODxzIN88US=>	NWTtU4pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
SK-BR-3	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFKwR\|IyKM7:TR?=	NGG4NpU2KGR?	MXjEUXNQ	MYXJR\|UxRDFizszN	NHWwd2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
UACC-732	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O1OFEh\|ryP	M3zEbFUh\A>?	NEO2cpdFVVOR	Mm\YTWM2ODxzIN88US=>	NV:5fHBNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-474	NHjue5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrZUJUyKM7:TR?=	NWThO2pDPSCm	NETKfZZFVVOR	NGjV[JdKSzVyPEGg{txO	M{HiZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC202	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmxJO69VQ>?	NGDUcFY2KGR?	MmDhSG1UVw>?	NFLocZRKSzVyPEGg{txO	M1\pbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
MCF7	M3Lwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLSNUDPxE1?	NEHyWpQ2KGR?	NFvlUXRFVVOR	MmDOTWM2ODxzIN88US=>	NH6yOHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MDA-MB-415	NHjyT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW1blIyKM7:TR?=	NGn0SIo2KGR?	MlzmSG1UVw>?	NH65bFdKSzVyPEGg{txO	NXrkO\|RPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-453	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxJO69VQ>?	MlzCOUBl	NI\Lc\|NFVVOR	NV3mbY9JUUN3MEyxJO69VQ>?	M{DaTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
ZR-75-1	NXnrb4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUOxJO69VQ>?	NFfDN3E2KGR?	MlvvSG1UVw>?	NXG3fHhUUUN3MEyxJO69VQ>?	NG\rfpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC38	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rnT\|Eh\|ryP	NVzDW5dTPSCm	NUTnfphiTE2VTx?=	M4fwU2lEPTB:MTFOwG0>	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1419	NGjWSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPicFEyKM7:TR?=	MmrROUBl	Mkn3SG1UVw>?	M4fLdWlEPTB:MTFOwG0>	M4H1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
UACC-812	NXfJd5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzueYZTOSEQvF2=	NEKzWY42KGR?	M4C1cmROW09?	Mn20TWM2ODxzIN88US=>	NIe0Wnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
HCC1187	NFXHd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnh[IkyKM7:TR?=	MWK1JIQ>	MkCzSG1UVw>?	M2nyTWlEPTB:MTFOwG0>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
KPL-1	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvlbJVSOSEQvF2=	MVq1JIQ>	M2HrS2ROW09?	Mn3JTWM2ODxzIN88US=>	NETjUng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
SUM-225	NHS3c5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXPPJAyKM7:TR?=	M2Kyd\|Uh\A>?	NIm1OnZFVVOR	NHfmPY9KSzVyPEGg{txO	NFrWfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
EFM-192A	NH60Z3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmD2NUDPxE1?	NEXVb5I2KGR?	M3zuUGROW09?	M{Hhe2lEPTB:MTFOwG0>	M17ifFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
JIMT-1	NYLhcWwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnyzNUDPxE1?	MWC1JIQ>	NGrubY1FVVOR	MkH4TWM2ODxzIN88US=>	NXz6WVN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1143	M13adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH4UYM5OSEQvF2=	M3TN[FUh\A>?	MWTEUXNQ	M{mwXGlEPTB:MTFOwG0>	M1;Fd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
HCC2218	NXztW2lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUKxJO69VQ>?	MUW1JIQ>	NWj2TZVTTE2VTx?=	MW\JR\|UxRDFizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-468	M1PsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTo[XhxOSEQvF2=	MWi1JIQ>	Mkm0SG1UVw>?	NW\1OoM6UUN3MEyxJO69VQ>?	NYPNcnI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-20	NYnOcZh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xJO69VQ>?	MYi1JIQ>	NX3NUWxITE2VTx?=	MY\JR\|UxRDFizszN	Mn3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-435	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:xJO69VQ>?	NFXNfXE2KGR?	NVzhUW9PTE2VTx?=	M36yVGlEPTB:MTFOwG0>	NVXDbZNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-549	NVfZT5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWxJO69VQ>?	MmfvOUBl	M{i0bWROW09?	M4rhWWlEPTB:MTFOwG0>	NYD3RoJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1806	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljmNUDPxE1?	NGnacmU2KGR?	MUDEUXNQ	MYDJR\|UxRDFizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1937	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TZSlEh\|ryP	MkHTOUBl	MnGzSG1UVw>?	NIWxSI5KSzVyPEGg{txO	MnS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
Hs578T	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2raNFEh\|ryP	NEPk[mM2KGR?	MmXlSG1UVw>?	M1\IfGlEPTB:MTFOwG0>	NGPEfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
MCF7	Mo[5R5l1d3SxeHnjJGF{e2G7		M{TYSVczKGh?	MoPzSG1UVw>?	MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKEV3NEXLJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMECxOVgh\|ryP	NXHVUYdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
DU145	NEPVcnZEgXSxdH;4bYMhSXO\|YYm=		MXu3NkBp	MkGzSG1UVw>?	NVvPbXgyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDMT2IyKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFA1OzVizszN	NIjMTpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780	NF\LO4dEgXSxdH;4bYMhSXO\|YYm=		MXK3NkBp	NH;2eXdFVVOR	M2mwRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO\|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2=	NHjSNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
U87MG	NXXFfXlvS3m2b4TvfIlkKEG\|c3H5		M4OzclczKGh?	MlLwSG1UVw>?	NIj3Vo9EgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3QThizszN	NGHCV5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780	NHT4ZYxHfW6ldHnvckBCe3OjeR?=		M4fUWFEhcA>?	NYfOWXhWTE2VTx?=	NVPPS5R[UW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2=	NHrnXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
DU145	Mm\RSpVv[3Srb36gRZN{[Xl?		NWe2N\|Z5OSCq	MXvEUXNQ	Ml\GTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1?	NGPEdWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780	M{\oNWZ2dmO2aX;uJGF{e2G7		NH7OVYsyKGh?	MWnEUXNQ	MVzJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCHQ{WwJI9nKDBwMEe0JO69VQ>?	NUX0ZVJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
MCF7	MWfGeY5kfGmxbjDBd5NigQ>?		NVGyb\|FROSCq	Ml3zSG1UVw>?	NX22NXhlUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgSVU1PUtibYX0ZY51NW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlEh\|ryP	M2jjflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
U87MG	MXPGeY5kfGmxbjDBd5NigQ>?		MVixJIg>	NVLZZ3BOTE2VTx?=	NWDORnFXUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?=	NWrsUVBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV\NPY52PzJiaB?=	MmTWSG1UVw>?	MnnqSWM2OD1yLkWyJO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
Huh7	M2[xZWZ2dmO2aX;uJGF{e2G7	MoPrNUDPxE1?	NG[wfY4yKGh?	NVm5RlRkTE2VTx?=	MVLJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>?	NUTYUppKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFQ1ODNpPkK1NFA1PDB\|PD;hQi=>
BNL	MYnGeY5kfGmxbjDBd5NigQ>?	MnK3NUDPxE1?	MYmxJIg>	NYfCboc1TE2VTx?=	NVfpfGx5UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4	M{naOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC0OFA{Lz5{NUCwOFQxOzxxYU6=
BON-1	NETycnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PDbVUxOCCwTR?=	NEn5VHAyOCCm	M2XzemROW09?	M1XTe2lvcGmkaYTzJINmdGxiZ4Lve5Rp	NEDHUo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
BON-1	NF7QfoRHfW6ldHnvckBCe3OjeR?=	Mn\5OVAxKG6P	NV\3PW1rPCCq	MUnEUXNQ	NULVem1WUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ\|MEigZY5lKFOnckS3Ny=>	NVm0UpJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
QGP-1	MXHGeY5kfGmxbjDBd5NigQ>?	MnnmOVAxKG6P	M3;2dlQhcA>?	MVHEUXNQ	Mkm2TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?=	MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
HCT-15	NVjrPIpmSXCxdH;zbZMhSXO\|YYm=	M2DLTFExKM7:TR?=	M364UlQ5KGh?	MVzEUXNQ	MknYTY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUG1JINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	NHHvOpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
HCT-116	NELDPFJCeG:2b4Ppd{BCe3OjeR?=	MXWxNEDPxE1?	M2fWd\|Q5KGh?	M2rOO2ROW09?	NV7uRoJ7UW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVEyPiClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	MmDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
NCI-H460	NX3iXoJzSXCxdH;zbZMhSXO\|YYm=	MmewNVAh\|ryP	M331SlQ5KGh?	MUXEUXNQ	NFvHS\|BKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	NEThdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
SKOV-3	NY[2fldXSXCxdH;zbZMhSXO\|YYm=	MUWxNEDPxE1?	Ml7SOFghcA>?	NUPzd\|VrTE2VTx?=	M{m3dmlv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
BSY-1	MWPBdI91d3OrczDBd5NigQ>?	M1;4O\|ExKM7:TR?=	M1PBXVQ5KGh?	M3nZWmROW09?	NXntNYZ[UW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	M1i0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-1	MVvBdI91d3OrczDBd5NigQ>?	MUKxNEDPxE1?	NFHtNXU1QCCq	MYLEUXNQ	NYLiPGI6UW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
NCI-H522	M2fQNmFxd3Sxc3nzJGF{e2G7	NXm5UXBnOTBizszN	NGXySmk1QCCq	Mmj2SG1UVw>?	NWrhbnNqUW6mdXPld{BieG:ydH;zbZM>	NWTBfFI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
OVCAR-3	NImze2pCeG:2b4Ppd{BCe3OjeR?=	NVqwXG5sOTBizszN	NWPxbYdyPDhiaB?=	MlXvSG1UVw>?	MkjVTY5lfWOnczDhdI9xfG:\|aYO=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
HBC-5	NYjnZmd3SXCxdH;zbZMhSXO\|YYm=	NFPIc5cyOCEQvF2=	M1H1TVQ5KGh?	M1\6[GROW09?	NFX3NG9KdmS3Y3XzJIFxd3C2b4Ppdy=>	M3r0ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
RXF-631L	MYnBdI91d3OrczDBd5NigQ>?	MXqxNEDPxE1?	M4G3UFQ5KGh?	MVvEUXNQ	MlXITY5lfWOnczDhdI9xfG:\|aYO=	M2i0UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-45	MkTYRZBwfG:\|aYOgRZN{[Xl?	NXPVUph6OTBizszN	NYSwd2J[PDhiaB?=	NETRUJpFVVOR	MWTJcoR2[2W\|IHHwc5B1d3Orcx?=	MlPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
LNCaP	MnLVSpVv[3Srb36gRZN{[Xl?	MkjHNUDPxE1?			NXfnNHhSW3WycILld5NmeyCyLVHLWEBt\X[nbIO=	NV;XRoJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlA4QTlpPkK1N\|YxPzl7PD;hQi=>
LNCaP95	MY\GeY5kfGmxbjDBd5NigQ>?	NXniXYR2OSEQvF2=			MUDTeZBxemW\|c3XzJJAuSUuWIHzleoVtew>?	NFfBbGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NFc6QSd-MkWzOlA4QTl:L3G+
A549	MkDiSpVv[3Srb36gRZN{[Xl?	MYe1NFAhdk1?	MXG0PEBp	NGLuW\|JFVVOR	MmOyTY5pcWKrdIOgRYt1KGGldHn2ZZRqd25?	MkPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{eyPVkoRjJ3OUO3Nlk6RC:jPh?=
A549	NVeyeY4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\LNUDPxE1?	M2\SNFczKGh?	NWD5WoJxTE2VTx?=	NFftOpRKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	M3zLO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO\|I6QTxxYU6=
H522	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX6[IwyKM7:TR?=	NYP5PFdjPzJiaB?=	NYfBR2t3TE2VTx?=	NF7PS2RKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NVnIUlRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|czQTlpPkK1PVM4Ojl7PD;hQi=>
SKMES-1	M2n0XGN6fG:2b4jpZ{BCe3OjeR?=	NIjpb44yKM7:TR?=	NHnsbYE4OiCq		NVzP[Y9qUW6mdXPld{Bk\WyuIHTlZZRp	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjBzM{OxPEc,OjZyMUOzNVg9N2F-
H596	MlewSpVv[3Srb36gRZN{[Xl?	NHO2b4cyKM7:TR?=			NGDNW4tKdXCjaYLzJINmdGxibXnndoF1cW:w	NH22fI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCxN\|MyQCd-Mk[wNVM{OTh:L3G+
HCC2450	NHjpWJdHfW6ldHnvckBCe3OjeR?=	Mkj1NUDPxE1?			MkDOTY1x[Wm{czDj[YxtKGmwdnHzbY9v	Mn;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN\|E5RC:jPh?=
HCT116	NV\BVmR3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWi3NkBpenN?		MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD60PEDPxE1w	M2D2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
MCF7	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M17CXFczKGi{cx?=		NF76WYtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGg{txONg>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
U87MG	NHPRNWVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2m1OlczKGi{cx?=		MoHORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXOEfNS{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT62OEDPxE1w	M{\vb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
A549	M4fE[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3\XV\|czKGi{cx?=		NV:wcpNoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlA4KM7:TT6=	NWLDbHZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O\|Y2QTB7PD;hQi=>
HeLa	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmLFO\|IhcHK\|		NVLTOno1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0MlM1KM7:TT6=	Mm\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
HCT116	NH;oRVVHfW6ldHnvckBie3OjeR?=	Mo\jNVAhfU1?	NV3QXHRyOSCqch?=		NUPLb4x{UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiQXv0JJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	NEPW[FI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
A2058 melanoma	NYDLbIJbS2WubDDjfYNt\SCjc4PhfS=>	NFfIWVQ2KHWP	MknMNlQhcHK\|		M{TuPGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGEzODV6IH3lcIFvd22jIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCVdXLHNUBxcGG\|ZTDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	MmLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
A2058 melanoma	M4XOT2NmdGxiY4njcIUh[XO\|YYm=	NHy4eWg2KHWP	MoTjNlQhcHK\|		M1fNTGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGEzODV6IH3lcIFvd22jIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCjbnHsfZNqew>?	NV[3dpJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
SKOV3	MlnFR4VtdCCleXPs[UBie3OjeR?=	M3zEN\|IhfU1?	NFG2[2MzPCCqcoO=		NEPEVmxE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBUU0:YMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEAzKHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh{OUW5Nkc,Ojh6Mkm1PVI9N2F-
SKOV3	Mkj1R4VtdCCleXPs[UBie3OjeR?=	MV[yJJVO	MlP4NlQhcHK\|		M4fVZWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHNMV1Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCVdXLHNUBxcGG\|ZTDheEAzKHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	NUjj[HR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
MDA-MB-231	NVH5cJpsS3m2b4TvfIlkcXS7IHHzd4F6		NH3tUW04OiCqcoO=		NFLsZ5VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlg5KM7:TT6=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
PC3	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=		MkLVO\|IhcHK\|		NIn2c4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvOzRizszNMi=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFyN{SyPUc,OjlzMEe0Nlk9N2F-
T47D	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		MWK3NkBpenN?		M4rjNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHQ1P0RiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFYvQTJizszNMi=>	M2D6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
MCF7	M1nTWWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVu3NkBpenN?		M3L0SmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEyNjB3IN88UU4>	M{DkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
TC32	MUTxTHRUKGG\|c3H5				M2fKVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MVzxTHRUKGG\|c3H5				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NGPMT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NUn5cGJteUiWUzDhd5NigQ>?				MkjtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M{TiVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M4XR[pFJXFNiYYPzZZk>				Mmi5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MUDxTHRUKGG\|c3H5				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MkW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NIm1bVlyUFSVIHHzd4F6				MkXtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NVe2TGR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MY\xTHRUKGG\|c3H5				MkjWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	M{f3VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NXrNT2RDeUiWUzDhd5NigQ>?				NFP2OW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	M4jOXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MkTxdWhVWyCjc4PhfS=>				MkW5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	M{H4S5FJXFNiYYPzZZk>				NW\pb4V3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MlO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M2rscJFJXFNiYYPzZZk>				MlKzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NWDkeXJEeUiWUzDhd5NigQ>?				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	NXPmSY06RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NHnRcolyUFSVIHHzd4F6				NG\Ye\|hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MmLkdWhVWyCjc4PhfS=>				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	MnS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MYrxTHRUKGG\|c3H5				NFHrSlJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	NGrpZoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NH\MfFByUFSVIHHzd4F6				NEfT[WhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M4jQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	M4TYZ5FJXFNiYYPzZZk>				MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	M1zJXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NYX2PGJseUiWUzDhd5NigQ>?				MnLrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	NWjnWVNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MnjZdWhVWyCjc4PhfS=>				M1LzVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	NWnKXW02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	M3\aVZFJXFNiYYPzZZk>				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?=	Mlq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MoDrdWhVWyCjc4PhfS=>				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NUOwOZdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M4HOO5FJXFNiYYPzZZk>				MlnjdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MlLjdWhVWyCjc4PhfS=>				Ml[xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	Mn:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NW\sdohveUiWUzDhd5NigQ>?				MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	Mnv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MoWzdWhVWyCjc4PhfS=>				NGK4S5RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	M{nZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NW[1bm5JeUiWUzDhd5NigQ>?				MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	M37BdZFJXFNiYYPzZZk>				NFG5[HhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NV\1RZZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
insect	NUDMdFNWTnWwY4Tpc44h[XO\|YYm=				MofrTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKaYOteIFo\2WmIIC4OYFteGijL4CxNVBidHCqYTDFOVQ2UyCvdYThcpQh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvODFzIN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB\|NE[wO{c,OzByM{S2NFc9N2F-
insect	MWXGeY5kfGmxbjDhd5NigQ>?				MkHOTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKaYOteIFo\2WmIIC4OYFteGijL4CxNVBidHCqYTDFOVQzUyCvdYThcpQh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvODJ7IN88UU4>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB\|NE[wO{c,OzByM{S2NFc9N2F-
Sf21	NYT0OZJxTnWwY4Tpc44h[XO\|YYm=		MlXrNUBpeg>?		M{fiOmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCyMUGw[IVtfGFxcnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKG2nYYP1doVlKGGodHXyJFEhcHJiYomgRYxmgGF4M{OgWJJi[2W{LXLhd4VlKG[udX;y[ZNk\W6lZTDwc4xieixiSVO1NEA:KDBwMUK1JO69VS5?	M3jXR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
MCF7	NY[5NXpESW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NELrWVU4OiCqcoO=		MkLCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHjhdoJwemmwZzDQTWs{S0FiRUW0OWshdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlIxPiEQvF2u	NFfSNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
Sf21	NVqw[nRQTnWwY4Tpc44h[XO\|YYm=		NHy2d3UyKGi{		NIXycY1KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwudGWwZ4ToJG4ufGW{bXnuZYwhUGm\|Nj30ZYdo\WRicEGxNIJmfGFxcnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigdFg2[WyyaHGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKG2nYYP1doVlKGGodHXyJFEhcHJiYomgRYxmgGF4M{OgWJJi[2W{LXLhd4VlKG[udX;y[ZNk\W6lZTDwc4xiemluIFnDOVAhRSByLkKzOEDPxE1w	NUfESZplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
T47D	M3TJU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXXtNXd{PzJiaILz		MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFR2N1SgZ4VtdHNiaHHyZo9zcW6pIGDJN2tESSCKMUC0O3IhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlI5PiEQvF2u	NGi3dHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzOFYxPyd-M{CwN\|Q3ODd:L3G+
PC3	NEnhbIlHfW6ldHnvckBie3OjeR?=		MXKyJIhzew>?		MVHJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bu\WG\|dYLl[EBi\nSncjCyJIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlM3PSEQvF2u	MlL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
HT-29	MlvjR4VtdCCleXPs[UBie3OjeR?=	NIThZXQxNjFzMTD0c{A{KHWP	M2rHZlI1KGi{cx?=		M1TvZWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFAvOTFzIITvJFMhfU1iYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSg[oxwfyCleYTvcYV1enl?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB\|NE[wO{c,OzByM{S2NFc9N2F-
A2058	M4PZW2Z2dmO2aX;uJIF{e2G7		M4rpdVEhcHJ?		NFfH[nFKdmirYnn0bY9vKG:oIGTPVmMzKGmwIHj1cYFvKEF{MEW4JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFCNQj;Bb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvPDF4IN88UU4>	M3vWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5\|MEO1PVAxOzxxYU6=
A2058	MV7GeY5kfGmxbjDhd5NigQ>?		NWK0OlhYOSCqch?=		NVrnVoNNUW6qaXLpeIlwdiCxZjDUU3JEOSCrbjDoeY1idiCDMkC1PEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVNjDwbI9{eGixconsZZRqd25iYYSgV4VzOjN3L{KzOkBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvPTV\|IN88UU4>	Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NUmwNFMoRjNyM{W5NFA{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

体内研究

BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。^[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。^[2]

激酶实验：^[2]	- 合并 PI3K 生化实验(ATP 消耗实验): BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：^[1]	- 合并 Cell lines: A2780细胞 Concentrations: 0-6.6 μM Incubation Time: 3天 Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔10³个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37^oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠 Dosages: ~60 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- 合并

溶解度 (25°C)

体外	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Buparlisib (BKM120) SDF

分子量	410.39
化学式	C₁₈H₂₁F₃N₆O₂
CAS号	944396-07-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NVP-BKM120

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	December 12 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

定制您的化合物库

Buparlisib (BKM120)

客户使用Selleck生产的Buparlisib (BKM120)发表文献222篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Buparlisib (BKM120) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品